Navigation Links
Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin,Emerging Growth Conference

BETHESDA, Md., July 05, 2007 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Officer of Micromet, Inc., will present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference in New York on Thursday, July 12, 2007 at 10:00am, eastern.

A webcast of Dr. Itin's remarks will be available live. You can access the webcast at: www.micromet-inc.com. An archived version of the remarks will also be available through the Company's web site for a limited time following the conference.

About Micromet, Inc. (www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Two product candidates are currently in clinical trials. MT103/MEDI-538, which is the first product candidate based on Micromet's novel BiTE(R) product development platform, is being evaluated in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. The BiTE product development platform is based on a unique, antibody-based format that leverages the cytotoxic potential of T cells, widely recognized as the most powerful 'killer cells' of the human immune system. Adecatumumab (MT201), a recombinant human monoclonal antibody which targets EpCAM expressing tumors, has completed two phase 2a clinical trials, one in patients with breast cancer and the other in patients with prostate cancer. In addition, a phase 1b trial evaluating the safety and tolerability of MT201 in combination with docetaxel is currently ongoing in patients with metastatic breast cancer. Micromet has established collaborations w
'"/>




Page: 1 2

Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:5/16/2008).../ -- Pulmo BioTech Inc. (OTC,Bulletin Board: PLMO....urpose of its Phase I Human Trials with its PulmoB... of Pulmonary Embolism and Pulmonary,Hypertension....ch subsidiary,PulmoScience Inc., and the title of...nd for Molecular Imaging of the Pulmonary Circulat...
(Date:5/16/2008)...strating that TYKERB and trastuzumab together resu...ession-free survival (PFS), -- Combining TYKERB a...de of the HER2 receptor may create a more complete... TYKERB alone despite patients,previous treatment...py, LONDON and PHILADELPHIA, May 16 /PRNewswire-U...
(Date:5/16/2008)...nificant Reductions in Selected ...shed in 2008 Proceedings of the American Society o...N DIEGO, May 16 /- ADVENTRX...ay that, in a registrational bioequivalence,clinic...nificant reduction,in general disorders and admini...
(Date:5/15/2008)...t safety profile of BSI-201 in sub...if., May 15 /- BiPar Sciences, Inc., ...ing novel cancer therapies,today announced that d...ill,be presented at the 2008 American Society of C...ings will be presented from the first in human Pha...
Breaking Medicine Technology:Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Remarks by President Bush and President Kikwete of Tanzania in an Exchange of Toasts 12112 1Remarks by President Bush and President Kikwete of Tanzania in an Exchange of Toasts 12112 2AAAS symposium to address significant effects of the male parent in reproductive success 12110 1Scientist postulates 4 aspects of humaniqueness differentiating human and animal cognition 2244 1Scientist postulates 4 aspects of humaniqueness differentiating human and animal cognition 2244 2Managing uncertainty important in ecological balance 3A ASU researcher 2242 1Managing uncertainty important in ecological balance 3A ASU researcher 2242 2
...chieved at 8 am versus placebo: - 25,/ - 13 mm Hg ...on dependent on vaccine dose and induced,antiangio...ented today at the Seventeenth European,Meeting on...), Switzerland and MILAN, Italy, June 17, 2007 -,C...ew clinical data,on its hypertension vaccine CYT00...
...007 - Genzyme Corp. (Nasdaq: GENZ),today announced...,form of Renvela™ (sevelamer carbonate) to R...luding one trial in which,patients received the po... was administered once per day. , Genzyme is devel...nal option for patients with chronic kidney diseas...
Other Medicine Technology:Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 2Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 3Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 4Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 5Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 6Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 7Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 8Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 9Genzyme Announces Results of Clinical Trials Investigating Powder,Form of Sevelamer Carbonate 2Genzyme Announces Results of Clinical Trials Investigating Powder,Form of Sevelamer Carbonate 3Genzyme Announces Results of Clinical Trials Investigating Powder,Form of Sevelamer Carbonate 4Genzyme Announces Results of Clinical Trials Investigating Powder,Form of Sevelamer Carbonate 5
(Date:5/16/2008)...alth Institute with 10,000 Sensual O Condom Packs ...Mansion Fundraiser, LOS ANGELES, May 16 /PRNewswi... B artist J Kwon known best for his hit song "Ever...ng the Urban Health Institute (UHI) with,10,000 Se... The donation is,being made to promote the launch ...
(Date:5/16/2008)... who would benefit most from chemo after surgery, ... News) -- A panel of 15 genes may help determine w... cancer will experience a recurrence and, therefor... shows. , By extension, the same genetic signa...ve forms of the cancer who would be able to forego...
(Date:5/16/2008)...RNewswire-USNewswire/ -- As tropical storms,contin...lta, survivors of,Cyclone Nargis are vulnerable to...s still need assistance, as exposure to the foul w...ly dire situation., "The people living in these c...this disaster and get back on their feet," said Da...
(Date:5/16/2008)...Death Drops More in 2007, WASHINGTON, May 16 /PRN...e in three cancer deaths, the National Cancer Inst...ion budget in lung cancer research in 2007,accord...liance (LCA) today., The two other federal agenci...nters for Disease Control and Prevention (CDC) and...
Breaking Medicine News(10 mins):Health News:Everybody in the Club Scream O! 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Myanmar Cyclone Survivors Face New Challenges 2Health News:Lung Cancer Still Lowest in Federal Funding 2
...ronic back pain shrinks the brain by as much as 11...of 10 to 20 years of aging.// Using magnetic reso...chniques, researchers compared the brain images of...to those of normal participants. The participants ...
...hat kids with asthma are more likely to experience...ike moving or family relationships. // 60 children...ied . None had a history of chronic stress. Over 1...rding asthma attacks and results of peak flow test...
...er job of keeping metabolism on track when people ...lping people keep the pounds off for good, shows a...white bread, refined breakfast cereals, and white ...ick rise in blood sugar and insulin. This in turn ...
...er non-steroidal anti-inflammatory pills, will not...oarthritis, // say researchers who analyzed the re...s. The study involved nearly 10,900 patients. Abo...00 received placebos. The average age of people in...
Other Medicine News:
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
Medicine Products: